Genmab A/S (GMAB)
35.45
+0.13
(+0.37%)
USD |
NASDAQ |
Sep 28, 15:15
Genmab Research and Development Expense (TTM) : 1.781B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.781B |
| March 31, 2026 | 1.692B |
| December 31, 2025 | 1.609B |
| September 30, 2025 | 1.465B |
| June 30, 2025 | 1.445B |
| March 31, 2025 | 1.437B |
| December 31, 2024 | 1.413B |
| September 30, 2024 | 1.313B |
| June 30, 2024 | 1.282B |
| March 31, 2024 | 1.191B |
| December 31, 2023 | 1.107B |
| September 30, 2023 | 1.051B |
| June 30, 2023 | 947.66M |
| March 31, 2023 | 860.35M |
| December 31, 2022 | 783.22M |
| September 30, 2022 | 757.81M |
| June 30, 2022 | 733.29M |
| March 31, 2022 | 699.20M |
| December 31, 2021 | 662.70M |
| September 30, 2021 | 611.54M |
| June 30, 2021 | 548.17M |
| March 31, 2021 | 513.29M |
| December 31, 2020 | 481.38M |
| September 30, 2020 | 432.15M |
| June 30, 2020 | 409.51M |
| Date | Value |
|---|---|
| March 31, 2020 | 379.86M |
| December 31, 2019 | 357.51M |
| September 30, 2019 | 328.22M |
| June 30, 2019 | 291.21M |
| March 31, 2019 | 257.41M |
| December 31, 2018 | 225.92M |
| September 30, 2018 | 199.60M |
| June 30, 2018 | 182.02M |
| March 31, 2018 | 160.88M |
| December 31, 2017 | 133.68M |
| September 30, 2017 | 118.54M |
| June 30, 2017 | 105.15M |
| March 31, 2017 | 103.77M |
| December 31, 2016 | 98.17M |
| September 30, 2016 | 95.77M |
| June 30, 2016 | 90.24M |
| March 31, 2016 | 78.21M |
| December 31, 2015 | 72.33M |
| September 30, 2015 | 68.51M |
| June 30, 2015 | 71.48M |
| March 31, 2015 | 78.73M |
| December 31, 2014 | 90.13M |
| September 30, 2014 | 94.05M |
| June 30, 2014 | 97.33M |
| March 31, 2014 | 98.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie, Inc. | 9.714B |
| Ascendis Pharma A/S | 315.81M |
| Zealand Pharma A/S | 286.45M |
| Bavarian Nordic A/S | 102.03M |
| Evaxion AS | 10.27M |